Best Life Sciences Companies in Baltimore, United States

Provider of DNA sequencing for cancer detection. The company's platform uses artificial intelligence and whole genome sequencing to detect unique patterns of DNA fragmentation in the blood of patients with cancer.

Funding rounds

• Dec 2025Conventional Debt$34.3M
• Jun 2024Series B—
• Jul 2022Series B$225M
• Jan 2021Series A$101.1M

Founders & team

Victor VelculescuFounder and Board of DirectorsSusan TousiCEO

Investors

Merck Global Health Innovation Fund, DFJ Growth, Lilly, Point72, Brown Advisory, Point Field Partners

A medical technology company developing drug delivery systems to treat brain diseases and disorders. It is a technology company that develops implantable devices for brain tumor treatment. Its flagship product, NeuroPASS, is a drug delivery system designed to bypass the blood-brain barrier using precise flow rate of medication directly to the brain for the treatment of aggressive brain tumors, Alzheimer’s, and Parkinson’s disease.

Funding rounds

• Jan 2026Grant (prize money)$1M
• Jan 2026Series B$19M
• Jun 2024Grant (prize money)$1M
• Sep 2022Series A$20M

Founders & team

Chad GordonFounder & CMOMichael MaglinCEO

Investors

Mumbai Angels, Lumis Partners, Maryland

Discovering and developing innovative biologics for immune disorders and cancers. The company focuses on modulating the immune system to create new treatment options for autoimmune diseases and cancers. They are advancing multiple drugs through clinical trials, including recombinant Fc fusion proteins designed to mimic or inhibit specific immune pathways. Their approach involves a team of talented scientists, board members, scientific advisors, and a network of global thought leaders. They aim to make a significant difference in the lives of individuals with immune disorders through innovative drug discovery and development. Their expertise lies in biologics, clinical trials, drug design, protein production, purification, and analysis, targeting autoimmune diseases and cancers.

Foundation focused on detection and prevention of fungal infections

Funding rounds

• Mar 2026Series B$11.2M
• Jun 2022Series A$3.5M
• Mar 2021Grant (prize money)$976.6K
• Jul 2015Grant (prize money)$175K

Founders & team

Kieren MarrFounder & CEO

Investors

HHS, TEDCO

Provider of single-molecule biosensors for cancer diagnostics. The company's semiconductor-based technology uses DNA supercoiling to convert nucleic acid hybridization into a mechanical signal for rapid diagnostics. The first application is for the detection of drug-resistant microbes, specifically tuberculosis.

Innovative upper limb myoelectric solutions improving lives through advanced technology. They build streamlined solutions for individuals with upper limb loss and difference, transforming laboratory research into real-world medical solutions. They focus on developing meaningful devices, offering reliable and comfortable prosthetic solutions. Their expertise lies in flexible electronics, hardware, advanced machine learning algorithm design, and app-based clinician and patient user interfaces. They are committed to innovation in upper limb prosthetics, leveraging leadership and technical expertise to make a meaningful impact. They develop and manufacture FDA Class 1 and Class 2, CE marked devices. They are rooted in research and development, creating innovative solutions for a niche market.

Developer of therapeutics for treatment of multiple diseses. It offers platform that screens libraries of hybrid macrocycles to discover lead compound rapafucin-FKBP complexes against novel and validated targets which include oncology, immunosuppression, ischemic reperfusion injury, and neurodegenerative diseases.

Funding rounds

• Sep 2025Series A—
• Jun 2024Series A$28M

Founders & team

Sean HuCEO

Investors

3E Bioventures Capital, Proxima Ventures, Lapam Capital, BioTrack Capital, Yonjin Capital

AgeneBio is developing therapeutics that prevent neurodegeneration and preserve & restore cognitive function for patients battling aMCI (pre-dementia stage of Alzheimer's), & other neurological and psychiatric diseases. AgeneBio’s Phase 3-ready lead candidate, AGB101, is targeting brain network imbalance and intend to treat aMCI & delay progression to Alzheimer’s dementia. Also has a small molecule discovery program to attenuate & control hippocampal overactivity with therapeutic potential for conditions including aMCI, autism, and schizophrenia.

Developer of RNA therapeutics to treat multiple diseases. The company is advancing controllable self-replicating RNA (c-srRNA) technology to develop therapies for a broad spectrum of diseases, rare diseases, aging-related disorders, and cancer.

Funding rounds

• Oct 2025Series A$4M
• Mar 2025Series A$3.6M
• Jan 2025Series A$600K
• Nov 2023Series A$7M

Founders & team

Minoru KoCo-Founder

Investors

NIH, HHS, UTEC

Developer of immunotherapy for bladder cancer. The lead candidate OS-101 is a STING agonist and BCG-based immunotherapy for bladder cancer that trigger proinflammatory innate immune responses against tumors.

Funding rounds

• Dec 2025Grant (prize money)$2.2M
• Jun 2024Grant (prize money)$270.2K
• Jun 2022Grant (prize money)$256K
• Sep 2021Grant (prize money)$2.2M

Founders & team

William Bill BishaiCo-FounderTrinity BivalacquaCo-Founder

Investors

HHS

Developer of vaccines for the treatment of cancer. The company is developing Anti-tumor Immune Redirection (AIR) a therapy that redirects the pre-existing immune memory from childhood vaccines or infections to fight cancer. They have developed a papillomavirus nanoparticle conjugated with viral antigens to treat cancer.

Funding rounds

• Apr 2025Grant (prize money)$470.4K
• Sep 2024Seed$4.5M
• Sep 2023Seed$3.1M
• Jul 2022Seed$2.5M

Founders & team

John TroyerFounder & COOJoshua WangFounder & CEO

Investors

America’s Seed Fund, Beiley Biofund, Proxima Ventures, Mana Ventures, Gaingels, SeedFolio

Provider of ultrasound-based imaging for Intraoperative detection of anastomotic blood clots. It helps in the detection of clots in surgical procedures to prevent morbid surgical failures. The two-part solution - EchoMark, an absorbable tissue marker to delineate the surgical site, and EchoFind, to guide users to the right position and extract blood flow data.